Failure of rituximab in relapsing neuromyelitis optica: Case report with two-year prospective follow-up;Échec thérapeutique du rituximab dans un cas de neuromyélite optique rémittente : suivi prospectif longitudinal sur deux ans

Revue Neurologique

Volumn 164, Issue 4, 2008, Pages 394-397

  Cassinotto, C ^a   Joux, J ^a   Chausson, N ^a   Smadja, D ^a   Cabre, P ^a  

^a Section of Radiology   (France)

Author keywords

MRI; Neuromyelitis optica; Rituximab; Treatment

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; MITOXANTRONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MYELOOPTIC NEUROPATHY; RELAPSE; SPINAL CORD ATROPHY; TREATMENT FAILURE; VISUAL ACUITY; ATROPHY; B LYMPHOCYTE; LYMPHOCYTE COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROSPECTIVE STUDY; RADIOGRAPHY; SPINAL CORD;

ADULT; ANTIBODIES, MONOCLONAL; ATROPHY; B-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MAGNETIC RESONANCE IMAGING; NEUROMYELITIS OPTICA; PLASMA EXCHANGE; PROSPECTIVE STUDIES; SPINAL CORD; VISUAL ACUITY;

EID: 45949108076     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2007.10.009     Document Type: Article

References (11)

1. Capobianco M., Malucchi S., di Sapio A., et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 28 (2007) 209-211
2. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., and Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 (2005) 1270-1272
3. Dietlein M., Pels H., Schulz H., et al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 74 (2005) 348-352
4. Harjunpaa A., Wiklund T., Collan J., et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 42 (2001) 731-738
5. Kranick S.M., Mowry E.M., and Rosenfeld M.R. Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 69 (2007) 704-706
6. Mandler R.N., Ahmed W., and Dencoff J.E. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51 (1998) 1219-1220
7. Rubenstein J.L., Fridlyand J., Abrey L., et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25 (2007) 1350-1356
8. Sibilia J., and Sordet C. [Rituximab: a original biotherapy in auto-immune disorders]. Rev Med Interne 26 (2005) 485-500
9. Watanabe S., Nakashima I., Miyazawa I., Shiga Y., Fujihara K., and Itoyama Y. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13 (2007) 128-132
10. Weinstock-Guttman B., Ramanathan M., Lincoff N., et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63 (2006) 957-963
11. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., and Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (1999) 1107-1114